376. Predictive Model for Fluconazole Resistance in Patient with Candida Bloodstream Infection
Session: Poster Abstract Session: Fungal Disease: Management and Outcomes
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • ID week18-Fluc R 2.pdf (318.8 kB)
  • Background:

    Candida bloodstream infection (CBSI) is associated with high morbidity and mortality. Guidelines recommend echinocandins as initial therapy, with fluconazole as an acceptable alternative in selected patients, including those at low risk for fluconazole resistance. We aimed to create a predictive model to identify patient at high risk of fluconazole resistance.

    Methods:

    We performed a retrospective analysis of hospitalized patients with CBSI at a large tertiary referral hospital between January 2007 and January 2015. Data were collected on demographics, comorbidities, medications, procedures, central lines, vital signs, and laboratory values. Univariate and Multivariable logistic regression analyses were used to build the predictive model. Variables with P<0.25 were considered for the multivariable analysis, and only those that remain significant (P<0.05) were retained in the final model.

    Results:

    We identified 1,083 patients with CBSI, of whom 684 patients had azole susceptibility data available. Among cases with available resistance data, C. glabrata was the most common species isolated, occurring in 240 cases (38%), followed by C. parapsilosis, 176 cases (25.7%), and C. albicans, 121 cases (17.6%). 139 isolates were found to have fluconazole resistance (C. glabrata 55, C. krusei 36). Eighty three variables were considered in the multivariable analysis; nine remained significant and were included in our final model. Variables associated with a higher risk of fluconazole resistance were: hematological cancer (OR 1.69 [95%CI 1.03, 2.79]), presence of an indwelling line (2.00 [1.30, 3.10]), prior fluconazole use (2.46 [1.32, 4.56]), prior voriconazole use (10.89 [1.18, 99.84]), prior calcineurin inhibitor use (2.65 [1.24, 5.66]), prior nitroimidazole use (1.63 [1.01, 2.64]), and prior tetracycline use (4.77 [1.96, 11.64]). Isolation of C. parapsilosis (0.20 [0.10, 0.39]), and chronic pulmonary disease (0.43 [0.21, 0.87]) were associated with a lower risk of resistance. The final model had a C-statistic of 0.75.

    Conclusion:

    We identified nine risk factors that were significantly associated with fluconazole resistance. By creating a predictive model, patients at higher or lower risk for resistance may be identified earlier which may assist in the choice of initial antifungal treatment.

    Abdullah Aljorayid, MD1, Ryan Kronen, B.A.2, Ana S. Salazar, MD3, Kevin Hsueh, MD1, Charlotte Lin, MD4, William Powderly, MD5 and Andrej Spec, MD5, (1)Infectious Disease, Barns Jewish Hospital/Washington University in St.Louis, St. Louis, MO, (2)Washington University School of Medicine in St. Louis, St. Louis, MO, (3)Washington University in St. Louis, School of Medicine, St. Louis, MO, (4)Internal Medicine, Washington University in St.Louis, St. Louis, MO, (5)Infectious Diseases, Barns Jewish Hospital/Washington University in St.Louis, St. Louis, MO

    Disclosures:

    A. Aljorayid, None

    R. Kronen, None

    A. S. Salazar, None

    K. Hsueh, None

    C. Lin, None

    W. Powderly, None

    A. Spec, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.